Abstract
Hepatitis C virus (HCV) infections are a serious viral health problem globally, causing liver cirrhosis and inflammation that can develop to hepatocellular carcinoma and death. Since the HCV NS3/4A protease complex cleaves the scissile peptide bond in the viral encoded polypeptide to release the non-structural proteins during the viral replication process, this protease is then an important target for drug design. The computer-aided drug design and screening targeted at NS3/4A protease of HCV were reviewed. In addition, using steered molecular dynamics simulations, potent inhibitors of the NS3/4A complex were searched for by screening the ZINC database based upon the hypothesis that a high rupture force indicates a high binding efficiency. Nine top-hit compounds (59500093, 59784724, 13527817, 26660256, 29482733, 25977181, 28005928, 13527826 and 13527826) were found that had the same or a greater maximum rupture force (and so assumed binding strength and inhibitory potency) than the four current drugs and so are potential candidates as anti- HCV chemotherapeutic agents. In addition, van der Waals interactions were found to be the main contribution in stabilizing the ligand- NS3/4A complex.
Keywords: NS3/4A protease, hepatitis C virus, steered molecular dynamics simulations.
Current Pharmaceutical Design
Title:In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
Volume: 20 Issue: 21
Author(s): Arthitaya Meeprasert, Thanyada Rungrotmongkol, Mai Suan Li and Supot Hannongbua
Affiliation:
Keywords: NS3/4A protease, hepatitis C virus, steered molecular dynamics simulations.
Abstract: Hepatitis C virus (HCV) infections are a serious viral health problem globally, causing liver cirrhosis and inflammation that can develop to hepatocellular carcinoma and death. Since the HCV NS3/4A protease complex cleaves the scissile peptide bond in the viral encoded polypeptide to release the non-structural proteins during the viral replication process, this protease is then an important target for drug design. The computer-aided drug design and screening targeted at NS3/4A protease of HCV were reviewed. In addition, using steered molecular dynamics simulations, potent inhibitors of the NS3/4A complex were searched for by screening the ZINC database based upon the hypothesis that a high rupture force indicates a high binding efficiency. Nine top-hit compounds (59500093, 59784724, 13527817, 26660256, 29482733, 25977181, 28005928, 13527826 and 13527826) were found that had the same or a greater maximum rupture force (and so assumed binding strength and inhibitory potency) than the four current drugs and so are potential candidates as anti- HCV chemotherapeutic agents. In addition, van der Waals interactions were found to be the main contribution in stabilizing the ligand- NS3/4A complex.
Export Options
About this article
Cite this article as:
Meeprasert Arthitaya, Rungrotmongkol Thanyada, Li Suan Mai and Hannongbua Supot, In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus, Current Pharmaceutical Design 2014; 20 (21) . https://dx.doi.org/10.2174/13816128113199990632
DOI https://dx.doi.org/10.2174/13816128113199990632 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In silico Designing and Screening of Lead Compounds to NS5-Methyltransferase of Dengue Viruses
Medicinal Chemistry Novel Synthetic Compounds as Potential Anticryptococcal Agents
Current Organic Synthesis Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels
Recent Patents on Anti-Infective Drug Discovery Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Antimicrobial and Structural Properties of Metal Ions Complexes with Thiosemicarbazide Motif and Related Heterocyclic Compounds
Current Medicinal Chemistry Adenosine Dysfunction in Epilepsy and Associated Comorbidities
Current Drug Targets Evasion of Host Immunity by Virulent Salmonella: Implications for Vaccine Design
Current Medicinal Chemistry The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection
Current Topics in Medicinal Chemistry A Potential Andrographolide Analogue against the Replication of Herpes Simplex Virus Type 1 in Vero Cells
Medicinal Chemistry Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) Vaccine Development for Alzheimers Disease
Current Pharmaceutical Design Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Leptinaemia and Antiendothelial Antibodies in Accelerated Atherosclerosis – Is There a Relationship?
Vascular Disease Prevention (Discontinued) Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) Recent Developments in Particulate-Based Vaccines
Recent Patents on Drug Delivery & Formulation Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals Advancement in Nanoparticle-based Biosensors for Point-of-care <i>In vitro</i> Diagnostics
Current Topics in Medicinal Chemistry Silkworm as a Host of Baculovirus Expression
Current Pharmaceutical Biotechnology